The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Cyclooxygenase in biology and disease
DuBois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B. A., & Lipsky, P. E. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.12.1063 · Cited by 2,506
Cyclooxygenase regulates angiogenesis induced by colon cancer cells
Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., & DuBois, R. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81433-6 · Cited by 2,272
Tsujii, M., & DuBois, R. N. (1995) · Cell · doi:10.1016/0092-8674(95)90127-2 · Cited by 2,267
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
Nelson, A. R., Fingleton, B., Rothenberg, M. L., & Matrisian, L. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1135 · Cited by 1,554
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, B. M., Edwards, D. A., Flickinger, A. G., Moore, R. J., & Seibert, K. (2000) · PubMed · Cited by 1,401
Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
Tsujii, M., Kawano, S., & DuBois, R. N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3336 · Cited by 1,398
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., & Dubois, R. N. (1998) · PubMed · Cited by 1,114
The implications of angiogenesis for the biology and therapy of cancer metastasis
Fidler, I. (1994) · Cell · doi:10.1016/0092-8674(94)90187-2 · Cited by 1,098
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., & Tarnawski, A. S. (2002) · Nature Medicine · doi:10.1038/nm0302-289 · Cited by 836
Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice
Liu, C. H., Chang, S.-H., Narko, K., Trifan, O. C., Wu, M.-T., Smith, E., Haudenschild, C., Lane, T. F., & Hla, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010787200 · Cited by 807
Inhibition of Angiogenesis In Vivo by Interleukin 12
Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., & Folkman, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.8.581 · Cited by 722
Host cyclooxygenase-2 modulates carcinoma growth
Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., & DuBois, R. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9621 · Cited by 673
Hsu, A.-L., Ching, T.-T., Wang, D.-S., Song, X., Rangnekar, V. M., & Chen, C.-S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.11397 · Cited by 671
Schmedtje, J. F., Ji, Y.-S., Liu, W.-L., DuBois, R. N., & Runge, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.1.601 · Cited by 668
Eliceiri, B. P., & Cheresh, D. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6869 · Cited by 649
Nör, J. E., Christensen, J., Mooney, D. J., & Polverini, P. J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65284-4 · Cited by 641
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Harris, R. E., Alshafie, G. A., Abou‐Issa, H., & Seibert, K. (2000) · PubMed · Cited by 540
Murohara, T., Horowitz, J. R., Silver, M., Tsurumi, Y., Chen, D., Sullivan, A., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.97.1.99 · Cited by 517
Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J., Zhu, L., Kronenberg, M., Miller, P. W., Portanova, J., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.361 · Cited by 465
Leahy, K. M., Ornberg, R., Wang, Y., Zweifel, B. S., Koki, A. T., & Masferrer, J. L. (2002) · PubMed · Cited by 438
Molecular pathology of cyclooxygenase-2 in neoplasia.
Fosslien, E. (2000) · PubMed · Cited by 394
Inhibition of Cyclooxygenase-2 Gene Expression by p53
Subbaramaiah, K., Altorki, N., Chung, W. J., Mestre, J. R., Sampat, A., & Dannenberg, A. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10911 · Cited by 355
Seno, H., Oshima, M., Ishikawa, T., Oshima, H., Takaku, K., Chiba, T., Narumiya, S., & Taketo, M. M. (2002) · PubMed · Cited by 327
Williams, C. S., Watson, A. J. M., Sheng, H., Helou, R. A., Shao, J., & DuBois, R. N. (2000) · PubMed · Cited by 318
3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon
Konerding, M. A., Fait, E., & Gaumann, A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1809 · Cited by 309
Arico, S., Pattingre, S., Bauvy, C., Gane, P., Barbat, A., Codogno, P., & Ogier-Denis, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201119200 · Cited by 303
Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor
Zachary, I. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1375 · Cited by 301
Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis.
Daniel, T. O., Liu, H., Morrow, J. D., et al. (1999) · PubMed · Cited by 295
Dormond, O., Foletti, A., Paroz, C., & Rüegg, C. (2001) · Nature Medicine · doi:10.1038/nm0901-1041 · Cited by 281
PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
Panigrahy, D., Singer, S., Shen, L. Q., Butterfield, C. E., Freedman, D. A., Chen, E. J., Moses, M. A., Kilroy, S., Duensing, S., Fletcher, C., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215634 · Cited by 276
Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor.
Kishi, K., Petersen, S. H., Petersen, C., Hunter, N. R., Mason, K. A., Masferrer, J. L., Tofilon, P. J., & Milas, L. (2000) · PubMed · Cited by 275
Altorki, N. K., Keresztes, R. S., Port, J. L., Libby, D. M., Korst, R. J., Flieder, D. B., Ferrara, C. A., Yankelevitz, D. F., Subbaramaiah, K., Pasmantier, M. W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.127 · Cited by 275
Dohadwala, M., Batra, R. K., Luo, J., Lin, Y., Krysan, K., Põld, M., Sharma, S., & Dubinett, S. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m210707200 · Cited by 260
Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
Teicher, B. A., Sotomayor, E. A., & Huang, Z. D. (1992) · PubMed · Cited by 260
Akt Takes Center Stage in Angiogenesis Signaling
Dimmeler, S., & Zeiher, A. M. (2000) · Circulation Research · doi:10.1161/01.res.86.1.4 · Cited by 260
Nor, J. E., Christensen, J. B., Liu, J., Peters, M., Mooney, D. J., Strieter, R. M., & Polverini, P. J. (2001) · PubMed · Cited by 257
Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws
Kaban, L. B., Troulis, M. J., Ebb, D., August, M., Hornicek, F. J., & Dodson, T. B. (2002) · Journal of Oral and Maxillofacial Surgery · doi:10.1053/joms.2002.34975 · Cited by 219
Liu, X. H., Kirschenbaum, A., Lu, M., Yao, S., Dosoretz, A., Holland, J. F., & Levine, A. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201095200 · Cited by 217
Petersen, C., Petersen, S. H., Milas, L., Lang, F. F., & Tofilon, P. J. (2000) · PubMed · Cited by 206
Cheng, T., Cao, W., Wen, R., Steinberg, R. H., & LaVail, M. M. (1998) · PubMed · Cited by 203
Rak, J., Filmus, J., & Kerbel, R. S. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00396-6 · Cited by 202
Mark, K. S., Trickler, W. J., & Miller, D. W. (2001) · PubMed · Cited by 197
The role of cyclooxygenase-2 in prostate cancer
Kirschenbaum, A., Liu, X.-H., Yao, S., & Levine, A. C. (2001) · Urology · doi:10.1016/s0090-4295(01)01255-9 · Cited by 182
Zhu, J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.23.1745 · Cited by 166
Dormond, O., Bezzi, M., Mariotti, A., & Rüegg, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209213200 · Cited by 152
Pore, N., Liu, S., Haas-Kogan, D. A., O’Rourke, D. M., & Maity, A. M. (2003) · PubMed · Cited by 151
Ueba, T., Nosaka, T., Takahashi, J. A., Shibata, F., Florkiewicz, R. Z., Vogelstein, B., Oda, Y., Kikuchi, H., & Hatanaka, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.9009 · Cited by 142
Inoue, H., Takamori, M., Shimoyama, Y., Ishibashi, H., Yamamoto, S., & Koshihara, Y. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704705 · Cited by 139
Ma, L., Soldato, P. D., & Wallace, J. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202392199 · Cited by 139
Rodrigues-Ferreira, S., Aken, E. V., Bocxlaer, S. V., Attoub, S., Nguyen, Q., Bruyneel, E. A., Westley, B. R., May, F. E. B., Thim, L., Mareel, M., et al. (2003) · The FASEB Journal · doi:10.1096/fj.02-0201com · Cited by 127
Yuan, A., Yu, C.-J., Luh, K.-T., Kuo, S.-H., Lee, Y.-C., & Yang, P.-C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.900 · Cited by 126
The Role of αv Integrins during Angiogenesis
Eliceiri, B. P., & Cheresh, D. A. (1998) · Molecular Medicine · doi:10.1007/bf03401768 · Cited by 119
Fong, C. Y., Pang, L., Holland, E. D., et al. (2000) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2000.279.1.l201 · Cited by 119
Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging
Li, W. W. (2000) · Academic Radiology · doi:10.1016/s1076-6332(00)80629-7 · Cited by 111
Self-citationCOX-2 Inhibition and Retinal Angiogenesis in a Mouse Model of Retinopathy of Prematurity
Wilkinson‐Berka, J. L., Alousis, N. S., Kelly, D. J., & Gilbert, R. E. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0392 · Cited by 105
Vaday, G. G., Schor, H., Rahat, M. A., Lahat, N., & Lider, O. (2001) · PubMed · Cited by 99
Jones, M. K., Szabó, I., Kawanaka, H., Husain, S. S., & Tarnawski, A. S. (2001) · The FASEB Journal · doi:10.1096/fj.01-0589fje · Cited by 98
Callejas, N. A., Casado, M., Díaz-Guerra, M. J. M., Boscá, L., & Martín‐Sanz, P. (2001) · Hepatology · doi:10.1053/jhep.2001.23002 · Cited by 96
Elder, D. J. E., Halton, D. E., Playle, L. C., & Paraskeva, C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10330 · Cited by 93
Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase A2.
Bicknell, R., & Vallée, B. L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.5.1573 · Cited by 93
Kedar, D. J., Baker, C. H., Killion, J. J., Dinney, C. P., & Fidler, I. J. (2002) · PubMed · Cited by 92
Mark, K. S., Trickler, W. J., & Miller, D. W. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29632-4 · Cited by 87
Herschman, H. R., Xie, W., & Reddy, S. T. (1995) · BioEssays · doi:10.1002/bies.950171207 · Cited by 86
Targeting Angiogenic Processes by Combination Rofecoxib and Ionizing Radiation
Dicker, A. P., Williams, T. L., & Grant, D. S. (2001) · American Journal of Clinical Oncology · doi:10.1097/00000421-200110000-00005 · Cited by 86
Saha, D., Datta, P. K., Sheng, H., Morrow, J. D., Wada, M., Moses, H. L., & Beauchamp, R. D. (1999) · Neoplasia · doi:10.1038/sj.neo.7900051 · Cited by 84
Gurubhagavatula, I., Amrani, Y., Praticò, D., Ruberg, F. L., Albelda, S. Μ., & Panettieri, R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci269 · Cited by 84
Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells
Parfenova, H., Parfenov, V. N., Shlopov, B. V., Levine, V., Falkos, S. A., Pourcyrous, M., & Leffler, C. W. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.281.1.c166 · Cited by 82
Vaday, G. G., Schor, H., Rahat, M. A., Lahat, N., & Lider, O. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.69.4.613 · Cited by 82
Galy, B., Créancier, L., Prado-Lourenço, L., Prats, A., & Prats, H. (2001) · Oncogene · doi:10.1038/sj.onc.1204630 · Cited by 61
Cyclooxygenase 2-mediated suppression of macrophage interleukin-12 production after thermal injury
Schwacha, M. G., Chung, C., Ayala, A., Bland, K. I., & Chaudry, I. H. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00357.2001 · Cited by 45
Cited by
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Inflammation: Gearing the journey to cancer
KUNDU, J., & SURH, Y. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.03.002 · Cited by 803
Mediators of vascular remodelling co-opted for sequential steps in lung metastasis
Gupta, G. P., Nguyen, D. X., Chiang, A. C., Bos, P. D., Kim, J. Y., Nadal, C., Gomis, R. R., Manova-Todorova, K., & Massagué, J. (2007) · Nature · doi:10.1038/nature05760 · Cited by 727
Integration of the extranuclear and nuclear actions of estrogen
Levin, E. R. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0390 · Cited by 708
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
Metadata
- Authors
- Gately, S., & Li, W. W.
- Venue
- Seminars in Oncology
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 31
- Issue
- 2 Suppl 7
- Pages
- 2-11
- ISSN
- 0093-7754 (ISSN-L)
- OpenAlex
- W2050658186
- Cited by
- 398
- References
- 85
- FWCI
- 20.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.